Use of a bioengineered antioxidant in mouse models of metabolic syndrome

被引:0
|
作者
Griffin, Deric M. [1 ]
Bitner, Brittany R. [1 ]
Ii, Zachary Criss [1 ]
Marcano, Daniela [2 ,3 ,4 ]
Berlin, Jacob M. [2 ,3 ,4 ,5 ]
Kent, Thomas A. [1 ,6 ,7 ]
Tour, James M. [2 ,3 ,4 ]
Samson, Susan L. [2 ,8 ]
Pautler, Robia G. [1 ,9 ]
机构
[1] Baylor Coll Med, Interdept Program Translat Biol & Mol Med, Houston, TX 77030 USA
[2] Rice Univ, Dept Chem, Houston, TX USA
[3] Rice Univ, Smalley Curl Inst, Houston, TX USA
[4] Rice Univ, Nanocarbon Ctr, Houston, TX USA
[5] City Hope Natl Med Ctr, Mol Med, Duarte, CA USA
[6] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA
[7] Michael E DeBakey VA Med Ctr, Ctr Translat Res Inflammatory Dis, Houston, TX USA
[8] Baylor Coll Med, Dept Med, Houston, TX 77030 USA
[9] Baylor Coll Med, Dept Mol Physiol & Biophys, One Baylor Plaza, Houston, TX 77030 USA
关键词
Obesity; metabolic syndrome; hyperglycemia; reactive oxygen species; oxidative stress; antioxidant; insulin resistance; prediabetes; NONALCOHOLIC FATTY LIVER; HYDROPHILIC CARBON CLUSTERS; OXIDATIVE STRESS; VITAMIN-E; CEREBROVASCULAR DYSFUNCTION; INSULIN-RESISTANCE; DISEASE; JNK; STEATOHEPATITIS; PATHOGENESIS;
D O I
10.1080/13543784.2020.1716216
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Oxidative stress has been implicated in metabolic syndrome (MetS); however, antioxidants such as vitamin E have had limited success in the clinic. This prompts the question of what effects amore potent antioxidant might produce. A prime candidate is the recently developed bioengineered antioxidant, poly(ethylene glycol)-functionalizedhydrophilic carbon clusters (PEG-HCCs), which are capable of neutralizing the reactive oxygen species (ROS) superoxide anion and hydroxyl radical at10(6)/molecule of PEG-HCC. In this project, we tested the potential of PEG-HCCs as a possible therapeutic for MetS. Results: PEG-HCC treatment lessened lipid peroxidation, aspartate aminotransferase levels, non-fastingblood glucose levels, and JNK phosphorylation inob/ob mice. PEG-HCC-treated WT mice had an increased response to insulin by insulin tolerance tests and adecrease in blood glucose by glucose tolerance tests. These effects were not observed in HFD-fed mice, regardless of treatment. PEG-HCCs were observed in the interstitial space of liver, spleen, skeletal muscle, and adipose tissue. No significant difference was shown in gluconeogenesis or inflammatory gene expression between treatment and dietary groups. Expert Opinion: PEG-HCCs improved some parameters of disease possibly due to a resulting increase in peripheral insulin sensitivity. However, additional studies are needed to elucidate how PEG-HCCsare producing these effects.
引用
收藏
页码:209 / 219
页数:11
相关论文
共 50 条
  • [21] Down syndrome and mouse models
    Kola, I
    Hertzog, PJ
    CURRENT OPINION IN GENETICS & DEVELOPMENT, 1998, 8 (03) : 316 - 321
  • [22] MOUSE MODELS FOR THE ANTIPHOSPHOLIPID SYNDROME
    GHARAVI, AE
    WILSON, WA
    LUPUS, 1993, 2 (05) : 289 - 290
  • [23] Mouse models of Apert syndrome
    Greg Holmes
    Child's Nervous System, 2012, 28 : 1505 - 1510
  • [24] Mouse models of Apert syndrome
    Holmes, Greg
    CHILDS NERVOUS SYSTEM, 2012, 28 (09) : 1505 - 1510
  • [25] Use of metabolic models in metabolic engineering.
    Forster, J
    Nielsen, D
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 225 : U210 - U210
  • [26] Antioxidant treatment normalizes mitochondrial energetics and myocardial insulin sensitivity independently of changes in systemic metabolic homeostasis in a mouse model of the metabolic syndrome
    Ilkun, Olesya
    Wilde, Nicole
    Tuinei, Joseph
    Pires, Karla M. P.
    Zhu, Yi
    Bugger, Heiko
    Soto, Jamie
    Wayment, Benjamin
    Olsen, Curtis
    Litwin, Sheldon E.
    Abel, E. Dale
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2015, 85 : 104 - 116
  • [27] Statin use in the metabolic syndrome
    Lundbye J.B.
    Thompson P.D.
    Current Atherosclerosis Reports, 2005, 7 (1) : 17 - 21
  • [28] Characterization of Reproductive, Metabolic, and Endocrine Features of Polycystic Ovary Syndrome in Female Hyperandrogenic Mouse Models
    Caldwell, A. S. L.
    Middleton, L. J.
    Jimenez, M.
    Desai, R.
    McMahon, A. C.
    Allan, C. M.
    Handelsman, D. J.
    Walters, K. A.
    ENDOCRINOLOGY, 2014, 155 (08) : 3146 - 3159
  • [29] Metabolic syndrome and the use of antipsychotics
    Vaios Peritogiannis
    Sofia Tsouli
    Spyros Zafiris
    Dimitrios Pappas
    Venetsanos Mavreas
    Annals of General Psychiatry, 5 (Suppl 1)
  • [30] Resveratrol Use in Metabolic Syndrome
    Bremer, Andrew A.
    METABOLIC SYNDROME AND RELATED DISORDERS, 2014, 12 (10) : 493 - 495